Sangon Biotech (revision 39)

Sangon Biotech (Shanghai) Co., Ltd. (trading as SGN; sangonbio.com) is a life-science reagent and peptide supplier trading as SGN from Shanghai, China, incorporated in 2004, whose catalogue spans research peptides alongside a broader range of laboratory reagents.^[1][2]

The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.^[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.^[4]

Incorporated in 2004, the organisation has one of the longer histories among the entities covered here.^[1] Its catalogue is notably broader than the research-peptide sector norm, extending into general laboratory reagents, oligonucleotides and molecular-biology consumables, and its name appears in technical contexts unrelated to the research-compound trade.^[2]

That breadth is the strongest element of its notability case and also the source of a scope question editors have discussed: an organisation whose peptide business is one line among many is not primarily a peptide supplier, and an article that treats it as one distorts what it is.

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Purchaser reports describe conventional practice for the peptide lines, with a batch certificate reporting purity and appearance, and water on some lots.^[5] Reagent-line reports describe documentation typical of the laboratory-supply trade — specification sheets and lot-specific certificates — which is a different documentary tradition from the research-compound sector and generally a more standardised one.

No certification claim has been independently corroborated here.^[2][6]

The reagent and oligonucleotide lines place this organisation in a different category from most covered here. Its inclusion in this wiki's supplier articles reflects its peptide listings, not the whole of its business.^[2]

Submitted reports on SGN peptide material to July 2026 are moderate in number. Reported area percent figures have been high and consistent with accompanying certificates.^[5]

Because the reagent business operates in a market with its own documentation conventions, purchasers have occasionally compared the two and found the reagent-line paperwork more standardised than the peptide-line paperwork.^[5] That comparison is within one organisation and is therefore more informative than a comparison across organisations, but it rests on a small number of reports.

The PeptidePedia tally records 751 self-reported submissions to July 2026. Recurring positive themes are catalogue breadth and documentation on the reagent lines; recurring complaints concern inconsistency between the two documentary traditions.^[4] Self-selected; reception rather than quality.^[4]

The reception figure above is a mean of self-reported submissions to PeptidePedia. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:

• Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
• It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
• It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.^[4]

The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.^[1]

Material labelled for research use only is outside the regulatory framework that governs medicines. Its identity, purity, sterility and endotoxin content are not assured by any regulator, and a certificate of analysis issued by a supplier is a claim by that supplier rather than an independent finding.^[3][7]

• Certificate of analysis
• Third-party testing
• Area percent purity
• Peptide content
• Research use only
• Peptide supply chain

• Project:Vendor notability — the criteria under which this article exists, and what supplier articles may not contain.
• Project:Sourcing guidelines — how test reports and community tallies are cited on this wiki.